Investigating IL-6 as a marker for chemotherapy sensitivity in AML
Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients
This study is testing if higher levels of a substance called IL-6 in bone marrow can help predict how well chemotherapy will work for people with Acute Myeloid Leukemia (AML).
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 72 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fujian Medical University Union Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06486350 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the levels of Interleukin-6 (IL-6) in bone marrow supernatant samples from patients diagnosed with Acute Myeloid Leukemia (AML). By correlating IL-6 levels with chemotherapy sensitivity, the study seeks to determine if elevated IL-6 can serve as a predictive biomarker for poor treatment outcomes. The findings may contribute to better risk stratification and personalized treatment approaches for AML patients. Participants will be required to provide informed consent and will be accompanied by family members during the study.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with their first onset of Acute Myeloid Leukemia who have not undergone prior chemotherapy.
Not a fit: Patients with concurrent malignancies, severe infections, or significant organ dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for AML patients by identifying those at higher risk of chemotherapy resistance.
How similar studies have performed: While the role of IL-6 in chemotherapy sensitivity has been suggested, this specific approach is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)"; 2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study; 3. Patients participate in the study accompanied by family members and sign informed consent documents. Exclusion Criteria: 1. Patients with concurrent malignancies requiring treatment; 2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV/AIDS; 3. Major surgery performed within the last 21 days; 4. Performance Status (PS) score \>3; 5. Severe liver or kidney dysfunction or serious infection; 6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.
Where this trial is running
Fuzhou, Fujian
- Fujian Medical University Union Hospital — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Huifang Huang
- Email: huanghuif@fjmu.edu.cn
- Phone: 13365910318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.